PRODUCT SRARCH
Welcome to use the web search system, you can enter the product name or product CAS number to search product . If you have any questions or sugesstions, please contact us.
|
Cas No. |
Product name |
755037-03-7 |
Regorafenib(BAY73-4506) |
more... |
Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, ... |
649735-63-7 |
Brivanib alaninate (BMS-582664) |
more... |
Brivanib alaninate (BMS-582664) is the prodrug of BMS-540215, an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM |
867160-71-2 |
Linsitinib(OSI906) |
more... |
OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, ... |
1089283-49-7 |
GSK1904529A |
more... |
GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc. |
1097917-15-1 |
ASP3026 |
more... |
ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. |
1356962-20-3 |
AZD3463 |
more... |
AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. |
1001350-96-4 |
BMS754807 |
more... |
BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, ... |
1256580-46-7 |
Alectinib (CH5424802) |
more... |
Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429. |
65678-07-1 |
AG1024 |
more... |
AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as... |
1197958-12-5 |
AP26113 |
more... |
AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2. |
|